Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 08, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,441.26 pence per share.
- Transaction Date: May 08, 2007.
Material Changes
Following the repurchase, the company's Treasury share holdings increased to 291,557,678 shares. The total number of shares in issue (excluding Treasury shares) stands at 5,727,985,588, which represents the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,727,985,588) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (291,557,678) for assessing potential future buyback capacity or share count dilution.
- Note that this filing is a transactional report and does not contain operational or financial performance data for the period.